BIIB or MNKD or XFOR
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s), and XFOR’s FA Score reflects 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- MNKD’s FA Score: 0 green, 5 red.
- XFOR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s), and XFOR’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- MNKD’s TA Score: 4 bullish, 5 bearish.
- XFOR’s TA Score: 4 bullish, 3 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +3.95% price change this week, while MNKD (@Biotechnology) price change was +5.49% , and XFOR (@Biotechnology) price fluctuated -34.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.43%. For the same industry, the average monthly price growth was +3.13%, and the average quarterly price growth was -5.44%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
MNKD is expected to report earnings on Aug 06, 2025.
XFOR is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+2.43% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+4.30% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | MNKD | XFOR | |
| Capitalization | 31.3B | 1.52B | 21.6M |
| EBITDA | 2.04B | 77.5M | -27.58M |
| Gain YTD | -19.219 | -22.239 | -83.074 |
| P/E Ratio | 26.95 | 50.00 | 1.77 |
| Revenue | 9.84B | 286M | 2.56M |
| Total Cash | 1.05B | 197M | 26.3M |
| Total Debt | 7.34B | 47.7M | 78.1M |
BIIB | MNKD | XFOR | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 19 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 63 Fair valued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 34 | 100 | |
SMR RATING 1..100 | 67 | 100 | 95 | |
PRICE GROWTH RATING 1..100 | 64 | 60 | 98 | |
P/E GROWTH RATING 1..100 | 97 | 96 | 98 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XFOR's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for MNKD (63) and is somewhat better than the same rating for BIIB (88). This means that XFOR's stock grew somewhat faster than MNKD’s and somewhat faster than BIIB’s over the last 12 months.
MNKD's Profit vs Risk Rating (34) in the Biotechnology industry is significantly better than the same rating for XFOR (100) and is significantly better than the same rating for BIIB (100). This means that MNKD's stock grew significantly faster than XFOR’s and significantly faster than BIIB’s over the last 12 months.
BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as XFOR (95) and is somewhat better than the same rating for MNKD (100). This means that BIIB's stock grew similarly to XFOR’s and somewhat faster than MNKD’s over the last 12 months.
MNKD's Price Growth Rating (60) in the Biotechnology industry is in the same range as BIIB (64) and is somewhat better than the same rating for XFOR (98). This means that MNKD's stock grew similarly to BIIB’s and somewhat faster than XFOR’s over the last 12 months.
MNKD's P/E Growth Rating (96) in the Biotechnology industry is in the same range as BIIB (97) and is in the same range as XFOR (98). This means that MNKD's stock grew similarly to BIIB’s and similarly to XFOR’s over the last 12 months.
| BIIB | MNKD | XFOR | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 66% | 3 days ago 82% | 3 days ago 88% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 82% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 54% | 3 days ago 80% | N/A |
| MACD ODDS (%) | 3 days ago 46% | 3 days ago 76% | 3 days ago 86% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 82% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 70% | 3 days ago 78% | 3 days ago 90% |
| Advances ODDS (%) | 5 days ago 53% | 5 days ago 82% | 26 days ago 80% |
| Declines ODDS (%) | 19 days ago 69% | 27 days ago 79% | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 83% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 74% | 3 days ago 90% |
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +2.15% | ||
| AMGN - BIIB | 47% Loosely correlated | -0.90% | ||
| NVS - BIIB | 46% Loosely correlated | +2.66% | ||
| PFE - BIIB | 43% Loosely correlated | +1.13% | ||
| OGN - BIIB | 39% Loosely correlated | +1.48% | ||
| SNY - BIIB | 38% Loosely correlated | +2.48% | ||
More | ||||
MNKD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To MNKD | 1D Price Change % | ||
|---|---|---|---|---|
| MNKD | 100% | +1.01% | ||
| VCYT - MNKD | 44% Loosely correlated | +2.15% | ||
| LXRX - MNKD | 42% Loosely correlated | -6.06% | ||
| INSM - MNKD | 40% Loosely correlated | -0.47% | ||
| BLUE - MNKD | 38% Loosely correlated | -2.47% | ||
| NRIX - MNKD | 37% Loosely correlated | +0.99% | ||
More | ||||
XFOR and
Correlation & Price change
A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with IMMP. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then IMMP could also see price increases.
| Ticker / NAME | Correlation To XFOR | 1D Price Change % | ||
|---|---|---|---|---|
| XFOR | 100% | -0.67% | ||
| IMMP - XFOR | 36% Loosely correlated | +2.40% | ||
| XCUR - XFOR | 34% Loosely correlated | +7.62% | ||
| SPHDF - XFOR | 34% Loosely correlated | N/A | ||
| CRDF - XFOR | 31% Poorly correlated | +4.06% | ||
| IMNM - XFOR | 29% Poorly correlated | -0.11% | ||
More | ||||